Status:
COMPLETED
Reference Population for Speckle Tracking Imaging
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Left Ventricular Function
Eligibility:
All Genders
20-80 years
Brief Summary
The SCAR study uses a software program entitled QLAB, a proprietory program, developed by Philips Healthcare (Philips Healthcare, Andover, MA). Literature on two-dimensional speckle tracking imaging (...
Eligibility Criteria
Inclusion
- Be between the ages of 20 - 80 years at study entry
- Provide written informed consent and be able to comply with study procedures, including permission to access medical records
- Have a BMI index equal to or less than 35
- Less than 5% risk of developing coronary artery disease as determined using the Combined Diamond/Forrester and CASS data (ACC Stable CAD Guidelines)
Exclusion
- Have taken cardioactive drugs within 6 months prior to examination
- These include but are not limited to beta-blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors
- Currently clinically significant chronic or acute illness
- Documented cardiovascular disease
- Possess abnormal cardiac structure and function after examination with routine ECHO
- This may include valvular defects, left ventricular hypertrophy, cardiomyopathies or pericardial disease
- Documented congenital heart conditions or defects
- History of diabetes
- Be unwilling to provide voluntary consent
Key Trial Info
Start Date :
December 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT01526252
Start Date
December 1 2011
End Date
January 1 2015
Last Update
April 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7